¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Need for immunization against viral hepatitis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prophylactic immunization
    ¿¹¹æ¸é¿ªÁ¢Á¾
  • passive immunization
    ¼öµ¿¸é¿ªÈ­
  • arthropod-borne viral disease
    ÀýÁöµ¿¹°¸Å°³¹ÙÀÌ·¯½ºº´
  • viral
    ¹ÙÀÌ·¯½º-
  • viral capsid
    ¹ÙÀÌ·¯½ºÄ¸½Ãµå
  • viral conjunctivitis
    ¹ÙÀÌ·¯½º°á¸·¿°
  • viral disease
    ¹ÙÀÌ·¯½ºº´
  • viral dysentery
    ¹ÙÀÌ·¯½ºÀÌÁú
  • viral hemagglutination
    ¹ÙÀÌ·¯½ºÀûÇ÷±¸ÀÀÁý
  • viral inclusion
    ¹ÙÀÌ·¯½ºÆ÷ÇÔ¹°
  • viral particle
    ¹ÙÀÌ·¯½ºÀÔÀÚ, ¹ÙÀ̸®¿Â
  • viral pneumonia
    ¹ÙÀÌ·¯½ºÆó·Å
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    ÀÚ°¡¸é¿ª°£¿°
  • acute hepatitis
    ±Þ¼º°£¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • viral capsid
    ¹ÙÀÌ·¯½ºÄ¸½Ãµå
  • epidermal-epithelial viral disease
    Ç¥ÇÇ»óÇǹÙÀÌ·¯½ºº´
  • viral disease
    ¹ÙÀÌ·¯½ºº´
  • viral dysentery
    ¹ÙÀÌ·¯½ºÀÌÁú
  • viral hemagglutination
    ¹ÙÀÌ·¯½ºÀûÇ÷±¸ÀÀÁý
  • viral inclusion
    ¹ÙÀÌ·¯½ºÆ÷ÇÔ¹°
  • viral particle
    ¹ÙÀÌ·¯½ºÀÔÀÚ
  • viral pneumonia
    ¹ÙÀÌ·¯½ºÆó·Å
  • viral
    ¹ÙÀÌ·¯½º-
  • alcoholic hepatitis
    ¾ËÄڿ𣿰
  • amebic hepatitis
    ¾Æ¸Þ¹Ù°£¿°
  • anicteric hepatitis
    ¹«È²´Þ°£¿°
  • autoimmune hepatitis
    (¢¡chronic active hepatitis) ¸¸¼ºÈ°µ¿°£¿°
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(ËçËÑËøÌ¡).
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(çãÛÁïÈðú).
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • immunization, passive
    ¼öµ¿¸é¿ª
  • immunization, prophylactic
    ¿¹¹æ¸é¿ª
  • HBc Ag => hepatitis B core antigen
    B Çü °£¿° c Ç׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBsAg => hepatitis B surface antigen
    B Çü °£¿° s Ç׿ø
  • HDAg => hepatitis D antigen
    D Çü °£¿°Ç׿ø
  • Halothane hepatitis
    ÇÒ·Îź°£¿°
  • Hepatitis
    °£¿°(ÊÜæú)
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
  • acute hepatitis
    ±Þ¼º °£¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • active immunization
    ´Éµ¿¸é¿ª(È­)(ÊÙÌ´).
  • deliberate immunization
    Àΰø¸é¿ª
  • immunization
    ¸é¿ª(¹ý)
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(çãÛÁïÈðú).
  • immunization
    ¸é¿ª(¹ý), ¿¹¹æÁ¢Á¾(ËçËÑËøÌ¡).
  • immunization therapy
    ¸é¿ª¿ä¹ý(¸é¿ª¿ä¹ý).
  • immunization therapy
    ¸é¿ª¿ä¹ý(Øóæ¹èþÛö).
  • immunization, active
    ´Éµ¿¸é¿ª, ´Éµ¿¸é¿ªÁ¶Ä¡
  • immunization, passive
    ¼öµ¿¸é¿ª
  • immunization, prophylactic
    ¿¹¹æ¸é¿ª
  • oral immunization
    °æ±¸¸é¿ª(¹ý)(ÌèÏ¢Øóæ¹Ûö).
  • oral immunization
    °æ±¸¸é¿ª(¹ý)(Ë­Ë´ËÎËçËÑ).
  • passive immunization
    ¼öµ¿¸é¿ª(áôÔÑØóæ¹).
  • prophylactic immunization
    ¿¹¹æÁ¢Á¾
  • acute infectious gastroenteritis =epidemic viral
    ±Þ¼ºÀü¿°¼ºÀ§Àå¿°(¡­îîæøêÖíóæú).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IgM¥áHBc IgM Antibody against Hepatitis B core Antigen
AVH Acute Viral hepatitis
CVH Chronic Viral Hepatitis
AVH acute viral hepatitis
VH vaginal hysterectomy; venous hematocrit; ventricular hypertrophy; veterans hospital; viral hepatitis...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CVH chronic viral hepatitis
VH-B viral hepatitis B
CON Certificate of Need
CII Childhood Immunization Initiative
CPITN Community Periodontal Index of Treatment Need
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hepatitis
    °£¿°
    °£ÀÇ ¿°Áõ¼º Áúȯ. °£Àå¿°À̶ó°íµµ ÇÑ´Ù. °£ ÁúȯÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÏ´Â °ÍÀ¸·Î¼­, Å©°Ô ±Þ¼º °£¿°°ú ¸¸¼º °£¿°À¸·Î ³ª´«´Ù. ¡¼±Þ¼º °£¿°¡½ ÀÌ º´¸íÀº ¸·¿¬ÇÑ ¸íĪÀ¸·Î¼­, °£ÀÇ ±Þ¼º, ½ÇÁú¼º »óÇØÀÇ °ÅÀÇ ÀüºÎ¸¦ Æ÷°ýÇÏ´Â ³ÐÀº °³³äÀÌÁö¸¸, ½ÇÁ¦´Â ¹ÙÀÌ·¯½ºÀÇ °¨¿°À¸·Î »ý±â´Â °£¿°ÀÌ ´ëºÎºÐÀ̰í, °£µ¶, È­ÇÐ ¾àǰ, ÀǾàǰ µîÀ¸·Î »ý±â´Â Áßµ¶¼º °£¿°µµ ºñ±³Àû ¸¹´Ù. ¹ÙÀÌ·¯½º¼º °£¿°Àº À¯Ç༺ °£¿°
  • hepatitis A
    AÇü °£¿°
    AÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â Àü¼¼°èÀûÀ¸·Î ºÐÆ÷µÈ ÀÚ±â ÇÑÁ¤¼º ¹ÙÀÌ·¯½º¼º ÁúȯÀ¸·Î¼­, À§»ý »óŰ¡ ³ª»Ú°í °æÁ¦ ¼öÁØÀÌ ³·Àº Áö¿ª¿¡ ´õ¿í ¸¹ÀÌ ¹ß»ýÇÏ¸ç ºñ°æ±¸Àû °¨¿°µµ °¡´ÉÇϱâ´Â Çϳª °ÅÀÇ ÀüÀûÀ¸·Î ´ëº¯ °æ±¸ °æ·Î¸¦ ÅëÇÏ¿© ÀüÆÄµÇ°í, º¸±ÕÀÚ »óÅ´ »ý±âÁö ¾Ê´Â´Ù. Àẹ ±â°£Àº 15-20ÀϷμ­ Æò±Õ 30ÀÏÀÌ´Ù. ´ë´Ù¼ö ȯÀÚ´Â ÀÓ»ó Áõ¼¼°¡ ¶Ñ·ÇÇÏÁö ¾Ê°Å³ª °æÇÑ °¨±â Áõ»óÀ» ³ªÅ¸³»¸ç Ȳ´ÞÀº ÀÖ´õ¶óµµ ¸Å¿ì °æ¹ÌÇÏ´Ù. ±¤¹üÀ§ÇÑ °£ ±«»ç°¡ ÀϾ ¼ö ÀÖÀ¸³ª BÇü °£¿°¿¡¼­ º¸´Ù´Â ÈξÀ Àû°Ô ³ªÅ¸³­´Ù.
  • hepatitis B
    BÇü °£¿°
    BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ °£ÀÇ ¿°Áõ¼º ÁúȯÀ¸·Î¼­ Àü¼¼°èÀûÀ¸·Î À¯ÇàÇϸç À¯ÇàÀÌ °¡Àå ³ôÀº Áö¿ªÀº Áß°î°ú µ¿³²¾Æ, »çÇ϶ó ÁÖº¯ ¾ÆÇÁ¸®Ä«, ÅÂÆò¾ç±ºµµÀÇ ´ëºÎºÐ ¹× ¾Æ¸¶Á¸ À¯¿ª µîÀÌ´Ù.
  • hepatitis B virus
    BÇü °£¿° ¹ÙÀÌ·¯½º
    1. BÇü °¨¿° ȯÀÚ¿¡¼­ ¸ðµç ü¾× ³»·Î ¹æÃâµÇ´Â ¹ÙÀÌ·¯½º. 2. »ç¶÷ÀÇ °£¿¡ »ì¸ç, Ç÷û °£¿° µîÀ» ÀÏÀ¸Å°´Â ¹ÙÀÌ·¯½º. HB ¹ÙÀÌ·¯½º¶ó°íµµ ÇÑ´Ù. HBs Ç׿ø, HBc Ç׿ø, HBe Ç׿ø µî ¼¼ Á¾·ùÀÇ Ç׿ø ´Ü¹éÁúÀ» Áö´Ñ ¹ÙÀÌ·¯½ºÀÌ´Ù. ÀÌ °¡¿îµ¥ HBs Ç׿ø¿¡´Â º¹¼öÀÇ Ç׿ø °áÁ¤±â°¡ ÀÖ¾î, ±× ¦¸ÂÃã¿¡ µû¶ó BÇü °£¿° ¹ÙÀÌ·¯½º´Â adr, adw, ayr, aywÀÇ 4°¡Áö ¾ÆÇüÀ¸·Î ³ª´©¾îÁ® ÀÖ´Ù. 1965³â ¹Ì±¹ÀÇ S. ºí·³¹ö±×°¡ ¿À½ºÆ®·¹Àϸ®¾Æ ¿øÁÖ¹ÎÀÇ Ç÷û¿¡¼­ ¹ß°ßÇÏ¿© ´çÃÊ¿¡´Â Ç׿ø¼ºÀÌ ÀÖ´Â ¹°ÁúÀ̶ó°í º¸°í, HB Ç׿ø ¶Ç´Â ¿À½ºÆ®·¹Àϸ®¾Æ Ç׿øÀ̶ó°í ºÒ·¶´Ù. ±× ÈÄ DNA
  • infectious hepatitis virus
    Àü¿°¼º °£¿° ¹ÙÀÌ·¯½º
  • lupoid hepatitis
    ·çÇÁ½º¾ç °£¿°, À¯³¶Ã¢ °£¿°
    ¼Ò±¸Áø»ó º´º¯À» Ư¡À¸·Î ÇÏ´Â À¯À°Á¾ÁõÀÇ °£¿°.
  • neonatal hepatitis
    ½Å»ý¾Æ °£¿°
  • serum hepatitis
    Ç÷û °£¿°
    ¹ÙÀÌ·¯½º¼º °£¿° Áß BÇü °£¿° ¹ÙÀÌ·¯½º¿¡ ÀÇÇÏ¿© °£ÀÌ Ä§ÇØµÇ´Â º´. Áõ¼¼´Â À¯Ç༺ °£¿°°ú º»ÁúÀûÀ¸·Î´Â ´Ù¸¦ ¹Ù°¡ ¾ø´Ù. ´Ù¼Ò ¿Ï¸¸ÇÏ°Ô ½ÃÀÛµÇÁö¸¸ °æ°ú°¡ ±æ°í, ¸¸¼ºÈ­ÀÇ °æÇâµµ °­ÇÏ´Ù. Àẹ±â´Â 60¡­90ÀÏÀε¥, ¼öÇ÷ ÈÄ 20ÀÏ Á¤µµ·Î ³ªÅ¸³ª´Â ¼öµµ ÀÖ´Ù. °¨¿° °æ·Î´Â Ç÷¾× ¹× Ç÷¾×Á¦Á¦
  • anti-viral agent
    Ç×¹ÙÀÌ·¯½ºÁ¦
    ¹ÙÀÌ·¯½º¸¦ º´¿øÃ¼·Î ÇÏ´Â Áúº´. Áï, Æ®¶óÄÚ¸¶¡¤¼Ò¾Æ¸¶ºñ
  • arthropod viral disease
    ¾Æ¸£º¸ ¹ÙÀÌ·¯½º Áúȯ, ÀýÁöµ¿¹° ¸Å°³ ¹ÙÀÌ·¯½º Áúȯ, ÀýÁöµ¿¹° ¸Å°³¼º ¹ÙÀÌ·¯½º Áúȯ
    µ¿ÀǾî=arbovirus disease.
  • arthropodborne viral fever
    ÀýÁöµ¿¹° ¸Å°³ÀÇ ¹ÙÀÌ·¯½º ¿­
  • chronic slow viral encephalitis
    ¸¸¼º Áö¿¬Çü ¹ÙÀÌ·¯½º¼º ³ú¿°
  • influenzal viral pneumonia
    ÀÎÇ÷翣ÀÚ Æó·Å
    ÀÎÇ÷翣ÀÚ¿¡ °É·Á ÀúÇ×·ÂÀÌ ÀúÇϵǾúÀ» ¶§ ±âµµ¿¡ ÀÖ´ø ¼¼±ÕÀÌ Áõ½ÄµÇ¾î ÀϾ´Â Æó·Å. ÀÌ¿Í °°ÀÌ 2Â÷ °¨¿°À» ÀÏÀ¸Å°´Â ¼¼±ÕÀº Æ÷µµ ±¸±Õ , Æó·Å ±¸±Õ , ¿¬¼â ±¸±Õ , ÀÎÇ÷翣ÀÚ ±Õ , Æó·Å °£±Õ µîÀÌ´Ù. º»ÁõÀÇ ÇÕº´·üÀº À¯Çà¿¡ µû¶ó Å« Â÷°¡ ÀÖÀ¸¸ç ¿¬·ÉÀûÀ¸·Î´Â ³ëÀÎÀÇ °æ¿ì¿¡ ³ô´Ù. Áõ¼¼´Â ÀÎÇ÷翣ÀÚÀÇ °í¿­ÀÌ 2¡­3ÀÏÀÌ µÇ¾îµµ ³»¸®Áö ¾Ê°í, ¶Ç´Â ÀÏ´Ü ³»·È´ø ¿­ÀÌ ´Ù½Ã »ó½ÂÇϸ鼭 È£Èí °ï¶õµµ ´õ¿í ½ÉÇØÁø´Ù. ÀÔ¼úÀ̳ª ¼Õ³¡Àº Â÷°¡¿öÁö°í ûÀÚ»öÀ» ¶í´Ù. ±âħ°ú ´ãµµ ¸¹À¸¸ç, ÈäºÎÀÇ Ã»Áø , ŸÁøÀ̳ª X¼± °Ë»ç¿¡¼­ Æó·ÅÀÇ ¼Ò°ßÀÌ Áõ¸íµÈ´Ù. Ä¡·á´Â 2Â÷ °¨¿°±Õ¿¡ ÀûÀÀµÇ´Â Ç×»ý ¹°ÁúÀ» ¾²´Â ¿Ü¿¡ ÀÏ¹Ý Æó·ÅÀÇ Ä¡·á¿¡ ÁØÇÑ´Ù. ³ëÀÎÀÇ °æ¿ì´Â »ç¸Á·üÀÌ ³ôÀ¸¸ç, ¶ÇÇÑ ÀÎÇ÷翣ÀÚ·Î »ç¸ÁÇÏ´Â »ç¶÷ÀÇ ¾à 80 %´Â Æó·ÅÀÇ ÇÕº´ ¶§¹®ÀÌ´Ù.
  • viral antibody
    ¹ÙÀÌ·¯½º Ç×ü
  • viral arthritis
    ¹ÙÀÌ·¯½º °üÀý¿°, ¹ÙÀÌ·¯½º¼º °üÀý¿°
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
viral hepatitis type E Hepatitis caused by a nonenveloped, single-stranded, positive-sense RNA virus 27-34 nm in diameter, unrelated to other hepatitis; it is the principal cause of enterically transmitted, waterborne, epidemic NANB hepatitis occurring primarily in Asia and Africa.
Synonym: hepatitis E.
(05 Mar 2000)
viral hepatitis vaccines Any vaccine raised against any virus or viral derivative that causes hepatitis.
(12 Dec 1998)
goose viral hepatitis An acute, highly fatal disease of goslings and Muscovy ducklings caused by the goose parvovirus and characterised by anorexia, feather loss, and tissue haemorrhages.
Synonym: Derzsy's disease.
(05 Mar 2000)
hepatitis, viral Liver inflammation caused by viruses. Specific hepatitis viruses have been labelled a, b, c, d, e, f, and g. While other viruses, such as the mononucleosis (epstein-barr) virus and cytomegalovirus, can also cause hepatitis, the liver is not their primary target.
(12 Dec 1998)
hepatitis, viral, animal Viral hepatitis in animals.
(12 Dec 1998)
hepatitis, viral, human Viral hepatitis in man.
(12 Dec 1998)
duck viral hepatitis An acute, highly contagious disease of young ducklings caused by an enterovirus and characterised by lethargy, spasmodic paddling and rapid death.
(05 Mar 2000)
active immunization The production of active immunity.
(05 Mar 2000)
anthrax immunization A series of six shots over six months and booster shots annually, the anthrax vaccine now in use in the USA was first developed in the 1950s and approved by the Food and Drug Administration for general use in 1970. It is produced by the Michigan Biologic Products Institute of Michigan's Department of Health and is given routinely to veterinarians and others working with livestock. In December, 1997 it was announced that all US military would receive the vaccine, as do the military in the UK and Russia, the reason being concern that anthrax might be used in biologic warfare.
(12 Dec 1998)
german measles immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (German measles). The MMR vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or MMR vaccination prior to entrance. Most children should receive MMR vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the MMR vaccine. Pregnant women should wait until after delivery before being immunised with MMR. People with HIV or AIDS should normally receive MMR vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
passive immunization The production of passive immunity.
(05 Mar 2000)
measles immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
chickenpox immunization This vaccine prevents the common disease known as chickenpox (varicella zoster). While chickenpox is often considered a trivial illness, it can cause significant lost time on the job and in school and have serious complications including ear infections, pneumonia, and infection of the rash with bacteria, inflammation of the brain (encephalitis) leading to difficulty with balance and coordination (cerebellar ataxia), damaged nerves (palsies), and Reye's syndrome, a potentially fatal complication. The vaccination requires only one shot given at about a year of age. If an older person has not had chickenpox, the shot may be given at any time. There have been few significant reactions to the chickenpox vaccine. All children, except those with a compromised immune system, should have the vaccination.
(12 Dec 1998)
rubella immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
mumps immunization The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á